Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018

  • Danbee Kang (Department of Clinical Research Design and Evaluation, SAISHT, Sungkyunkwan University) ;
  • Sungkeun Shim (Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medi) ;
  • Juhee Cho (Department of Clinical Research Design and Evaluation, SAISHT, Sungkyunkwan University) ;
  • Hyo Keun Lim (Department of Health Sciences and Technology, SAISHT, Sungkyunkwan University)
  • Received : 2019.10.30
  • Accepted : 2020.02.25
  • Published : 2020.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

We reviewed all studies assessing the health-related quality of life (HRQoL) in patients with hepatocellular carcinoma (HCC) between 2009 and 2018 (n = 45). Most studies assessed HRQoL as an outcome, and evaluated or compared the HRQoL of HCC patients depending on the type of treatment or stage of disease. HCC patients had a worse HRQoL than the general population, including in those with early-stage HCC. Patients commonly experienced pain, fatigue, sleep disturbance, distress, and lack of appetite, and these symptoms remained problematic even a few years after treatment. TNM classification of malignant tumors stage, tumor stage, presence of cirrhosis, being Asian, being female, living alone, or being unemployed were associated with a poor HRQoL. While recent studies have included a more diverse patient population, various topics, and different study designs, there were limited studies on supportive interventions. Given the increase in HCC cases and HCC survivors, addressing the HRQoL of HCC patients requires more attention.

Keywords

References

  1. Hays RD, Reeve BB. Measurement and modeling of healthrelated. In: Kellewo J, Heggenhougen HK, Quah SR, eds. Epidemiology and demography in public health. San Diego, CA: Elsevier, 2010:195-205. 
  2. Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 2008;70:353-360  https://doi.org/10.1016/j.ijrobp.2007.06.024
  3. Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 2009;27:5816-5822  https://doi.org/10.1200/JCO.2009.23.7420
  4. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008;26:3770-3776  https://doi.org/10.1200/JCO.2007.14.6647
  5. Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol 2014;32:2920-2927  https://doi.org/10.1200/JCO.2014.55.0707
  6. Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep 2019;21:17 
  7. Yoon SK, Chun HG. Status of hepatocellular carcinoma in South Korea. Chin Clin Oncol 2013;2:39 
  8. De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, et al. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168-176  https://doi.org/10.1136/gutjnl-2018-318193
  9. Sun VC, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs 2008;12:759-766  https://doi.org/10.1188/08.CJON.759-766
  10. Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20:1042-1113  https://doi.org/10.3348/kjr.2019.0140
  11. Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol 2017;8:789-798  https://doi.org/10.21037/jgo.2017.06.16
  12. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624 
  13. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56 Suppl 1:S75-S87  https://doi.org/10.1016/S0168-8278(12)60009-9
  14. Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol 2016;27:856-861  https://doi.org/10.1093/annonc/mdw054
  15. Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol 2010;8:559-564  https://doi.org/10.1016/j.cgh.2010.03.008
  16. Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol 2014;5:296-317 
  17. Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician's perspective. World J Hepatol 2017;9:867-883  https://doi.org/10.4254/wjh.v9.i20.867
  18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700 
  19. Sterne JA, Hernan MA, Reeves BC, Savovic' J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919 
  20. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483  https://doi.org/10.1097/00005650-199206000-00002
  21. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376  https://doi.org/10.1093/jnci/85.5.365
  22. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579  https://doi.org/10.1200/JCO.1993.11.3.570
  23. Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer 2004;40:2439-2444  https://doi.org/10.1016/j.ejca.2004.06.033
  24. Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 2002;20:2229-2239  https://doi.org/10.1200/JCO.2002.07.093
  25. Yount S, Cella D, Webster K, Heffernan N, Chang C, Odom L, et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manage 2002;24:32-44  https://doi.org/10.1016/S0885-3924(02)00422-0
  26. Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study. J Gastroenterol Hepatol 2015;30:1167-1174  https://doi.org/10.1111/jgh.12920
  27. Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, et al. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer 2013;21:475-483  https://doi.org/10.1007/s00520-012-1541-5
  28. Kaiser K, Mallick R, Butt Z, Mulcahy MF, Benson AB, Cella D. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Support Care Cancer 2014;22:919-926  https://doi.org/10.1007/s00520-013-2039-5
  29. Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol 2010;21:1024-1030  https://doi.org/10.1016/j.jvir.2010.03.005
  30. Fan SY, Eiser C. Illness experience in patients with hepatocellular carcinoma: an interpretative phenomenological analysis study. Eur J Gastroenterol Hepatol 2012;24:203-208  https://doi.org/10.1097/MEG.0b013e32834ec184
  31. Toro A, Pulvirenti E, Palermo F, Di Carlo I. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol 2012;21:e23-e30  https://doi.org/10.1016/j.suronc.2011.10.005
  32. Chie WC, Yu F, Li M, Baccaglini L, Blazeby JM, Hsiao CF, et al. Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Qual Life Res 2015;24:2499-2506  https://doi.org/10.1007/s11136-015-0985-8
  33. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013;11:1358-1365.e1  https://doi.org/10.1016/j.cgh.2013.04.028
  34. Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013;108:1252-1259  https://doi.org/10.1038/bjc.2013.85
  35. Kolligs FT, Bilbao JI, Jakobs T, Inarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int 2015;35:1715-1721  https://doi.org/10.1111/liv.12750
  36. Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, et al. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open 2016;6:e010696 
  37. Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol 2017;209:430-434  https://doi.org/10.2214/AJR.16.17477
  38. Huang G, Chen X, Lau WY, Shen F, Wang RY, Yuan SX, et al. Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. Br J Surg 2014;101:1006-1015  https://doi.org/10.1002/bjs.9539
  39. Lei JY, Yan LN, Wang WT, Zhu JQ, Li DJ. Health-related quality of life and psychological distress in patients with early-stage hepatocellular carcinoma after hepatic resection or transplantation. Transplant Proc 2016;48:2107-2111  https://doi.org/10.1016/j.transproceed.2016.04.012
  40. He Q, Jiang JJ, Jiang YX, Wang WT, Yang L. Health-related quality of life comparisons after radical therapy for early-stage hepatocellular carcinoma. Transplant Proc 2018;50:1470-1474  https://doi.org/10.1016/j.transproceed.2018.04.041
  41. Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, et al. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer 2016;16:878 
  42. Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, Huang ZQ, et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: a prospective randomized controlled study. Chin J Integr Med 2010;16:102-108  https://doi.org/10.1007/s11655-010-0102-3
  43. Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol 2016;26:3492-3499  https://doi.org/10.1007/s00330-016-4207-8
  44. Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, et al. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer 2011;105:945-952  https://doi.org/10.1038/bjc.2011.333
  45. Kuroda H, Ushio A, Miyamoto Y, Sawara K, Oikawa K, Kasai K, et al. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010;25:1550-1555  https://doi.org/10.1111/j.1440-1746.2010.06306.x
  46. Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, et al. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Asia Pac J Clin Oncol 2017;13:e304-e311  https://doi.org/10.1111/ajco.12464
  47. Mise Y, Satou S, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, et al. Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg 2014;38:958-967  https://doi.org/10.1007/s00268-013-2342-9
  48. Mikoshiba N, Miyashita M, Sakai T, Tateishi R, Koike K. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life. Psychooncology 2013;22:2347-2353  https://doi.org/10.1002/pon.3300
  49. Qiao CX, Zhai XF, Ling CQ, Lang QB, Dong HJ, Liu Q, et al. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012;18:2689-2694  https://doi.org/10.3748/wjg.v18.i21.2689
  50. Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res 2015;24:1669-1675  https://doi.org/10.1007/s11136-014-0895-1
  51. Jie B, Qiu Y, Feng ZZ, Zhu SN. Impact of disclosure of diagnosis and patient autonomy on quality of life and illness perceptions in Chinese patients with liver cancer. Psychooncology 2016;25:927-932  https://doi.org/10.1002/pon.4036
  52. Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients with hepatocellular carcinoma near the end of life: a longitudinal qualitative study of their illness experiences. Cancer Nurs 2015;38:E19-E27  https://doi.org/10.1097/NCC.0000000000000188
  53. Mikoshiba N, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, et al. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Health Qual Life Outcomes 2012;10:58 
  54. Yang Z, Wan C, Li W, Cun Y, Meng Q, Ding Y, et al. Development and validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for patients with hepatocellular carcinoma. Cancer Invest 2015;33:340-346  https://doi.org/10.3109/07357907.2015.1036280
  55. Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, et al. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology 2012;55:1122-1129  https://doi.org/10.1002/hep.24798
  56. Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouche O, et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013;58:509-521  https://doi.org/10.1016/j.jhep.2012.11.019
  57. Li L, Mo FK, Chan SL, Hui EP, Tang NS, Koh J, et al. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma-clinical application of health-related quality-of-life data. BMC Cancer 2017;17:8 
  58. Diouf M, Bonnetain F, Barbare JC, Bouche O, Dahan L, Paoletti X, et al. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist 2015;20:62-71  https://doi.org/10.1634/theoncologist.2014-0175
  59. Hsu WC, Tsai AC, Chan SC, Wang PM, Chung NN. Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan. Nutr Cancer 2012;64:543-549  https://doi.org/10.1080/01635581.2012.675620
  60. Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012;17:732-739  https://doi.org/10.1634/theoncologist.2011-0368
  61. Fan SY, Eiser C, Ho MC, Lin CY. Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology 2013;22:1353-1360  https://doi.org/10.1002/pon.3146
  62. Butt Z, Lai JS, Beaumont JL, Kaiser K, Mallick R, Cella D, et al. Psychometric properties of a brief, clinically relevant measure of pain in patients with hepatocellular carcinoma. Qual Life Res 2014;23:2447-2455  https://doi.org/10.1007/s11136-014-0692-x
  63. Phillips R, Gandhi M, Cheung YB, Findlay MP, Win KM, Hai HH, et al. Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30. J Clin Epidemiol 2015;68:895-902  https://doi.org/10.1016/j.jclinepi.2015.02.011
  64. Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, et al. Health-related quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-1566  https://doi.org/10.1007/s00270-017-1681-6
  65. Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF. Symptom distress in patients with hepatocellular carcinoma toward the end of life. Oncol Nurs Forum 2017;44:665-673  https://doi.org/10.1188/17.ONF.665-673
  66. Gill J, Baiceanu A, Clark PJ, Langford A, Latiff J, Yang PM, et al. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncol 2018;14:1701-1710  https://doi.org/10.2217/fon-2017-0715
  67. Kensinger CD, Feurer ID, O'Dell HW, LaNeve DC, Simmons L, Pinson CW, et al. Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma. Clin Transplant 2016;30:1036-1045  https://doi.org/10.1111/ctr.12785
  68. Qiu B, Li K, Dong X, Liu FQ. Transjugular intrahepatic portosystemic shunt for portal hypertension in hepatocellular carcinoma with portal vein tumor thrombus. Cardiovasc Intervent Radiol 2017;40:1372-1382  https://doi.org/10.1007/s00270-017-1655-8
  69. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer 2017;81:17-25  https://doi.org/10.1016/j.ejca.2017.05.001
  70. He Q, Jiang JJ, Jiang YX, Wang WT, Yang L; Liver Surgery Group. Health-related quality of life comparisons after radical therapy for early-stage hepatocellular carcinoma. Transplant Proc 2018;50:1470-1474  https://doi.org/10.1016/j.transproceed.2018.04.041
  71. Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75